Can u create a diagram of brain tumors
Generating Image
Here's a diagram of brain tumors showing their typical anatomical locations within the brain. Here's a quick summary of the key tumors shown:
Primary Brain Tumors (originate in brain tissue):
- Glioblastoma (GBM) - Most aggressive malignant tumor, arises in the cerebral hemispheres
- Astrocytoma - Arises from astrocytes in the cerebral cortex; ranges from low to high grade
- Meningioma - Grows from the meninges (brain lining); usually benign
- Medulloblastoma - Found in the cerebellum; most common malignant brain tumor in children
- Ependymoma - Arises near the ventricles from ependymal cells
- Pituitary Adenoma - Benign tumor at the pituitary gland; can affect hormones and vision
- Craniopharyngioma - Near the hypothalamus/pituitary stalk; often affects children
- Acoustic Neuroma (Schwannoma) - Benign tumor on cranial nerve VIII; causes hearing loss
Secondary (Metastatic) Tumors spread to the brain from cancers elsewhere in the body (lung, breast, melanoma are most common).
Let me know if you'd like a more detailed breakdown of any specific tumor type!
Create a comparison table of tumor grades and prognosis
Reading File
Finding Sources
Searching PubMed
brain tumor WHO grade classification prognosis survival
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I now have enough data from the textbooks to build a thorough, well-sourced comparison table. Here it is:
Brain Tumor Grades and Prognosis - Comparison Table
Based on the WHO CNS Tumor Classification (updated 2021) and current textbook data:
WHO Grading System Overview
The WHO grades CNS tumors on a scale of 1 to 4 based on histological features: cellularity, nuclear atypia, mitotic activity, endovascular hyperplasia, and necrosis.
| WHO Grade | Descriptors | Growth Rate | Key Histological Features |
|---|---|---|---|
| Grade 1 | Benign | Slow | Low cellularity, no mitoses, no necrosis |
| Grade 2 | Low-grade malignant | Slow-moderate | Mild atypia, rare mitoses, no necrosis |
| Grade 3 | Anaplastic (high-grade) | Moderate-fast | High mitoses, nuclear atypia, no necrosis |
| Grade 4 | Malignant (high-grade) | Fast | Necrosis + microvascular proliferation (required) |
Tumor-by-Tumor: Grade, Prognosis & Survival
| Tumor Type | WHO Grade | Benign/Malignant | Median Survival | 5-Year Survival | Key Prognostic Factors |
|---|---|---|---|---|---|
| Pilocytic Astrocytoma | Grade 1 | Benign | >10 years | ~90% | Complete resection curative; circumscribed, non-infiltrating |
| Diffuse Astrocytoma | Grade 2 | Low-grade malignant | ~8 years | ~50-70% | IDH mutation status (IDH-mutant = better prognosis) |
| Anaplastic Astrocytoma | Grade 3 | Malignant | 2-3 years | ~20-30% | IDH status, MGMT methylation, extent of resection |
| Glioblastoma (GBM) | Grade 4 | Highly malignant | ~12-15 months | ~5-10% | MGMT promoter methylation improves response to temozolomide |
| Oligodendroglioma (low-grade) | Grade 2 | Low-grade malignant | ~7 years | ~60-70% | 1p/19q co-deletion = better chemo response (PCV/temozolomide) |
| Oligodendroglioma (anaplastic) | Grade 3 | Malignant | ~2 years | ~30-40% | Better overall than astrocytoma at same grade |
| Meningioma | Grade 1 (80-85%) | Benign | Excellent (decades) | >80% | Surgical accessibility, size, location; low recurrence after resection |
| Atypical Meningioma | Grade 2 | Borderline | 5-15 years | ~50-70% | High mitotic index; higher recurrence risk |
| Anaplastic Meningioma | Grade 3 | Malignant | 1.5-3 years | ~<30% | BAP1 mutation, TERT promoter mutation = worse prognosis |
| Medulloblastoma | Grade 4 | Malignant | Variable | ~75% (treated) | Highly radiosensitive; WNT subtype >90% survival; ETMR <20% |
| Ependymoma | Grade 2-3 | Low-moderate malignant | Variable | ~50-75% | Infratentorial location; complete resection + radiation improves survival |
| Pituitary Adenoma | Grade 1 (non-WHO) | Benign | Excellent | >95% | Hormone-secreting vs. non-secreting; rarely malignant (pituitary carcinoma) |
| Craniopharyngioma | Grade 1 | Benign (locally aggressive) | Decades | ~85-90% | High recurrence rate; vision/endocrine damage common |
| Acoustic Neuroma (Schwannoma) | Grade 1 | Benign | Excellent | >95% | No malignant transformation; cranial nerve preservation key |
| CNS Lymphoma (Primary) | Grade 4-equivalent | Malignant | 2-4 years (with tx) | ~30-40% | Chemosensitive; methotrexate-based regimens; immunocompromised = worse |
| Brain Metastases | N/A (secondary) | Malignant | 4-12 months | <10% | Number of lesions, KPS score, primary tumor control (RPA class) |
Key Molecular Markers Affecting Prognosis
| Marker | Found in | Prognostic Impact |
|---|---|---|
| IDH1/IDH2 mutation | Astrocytoma, Oligodendroglioma | Favorable - longer survival |
| MGMT methylation | GBM, Anaplastic gliomas | Predicts response to temozolomide |
| 1p/19q co-deletion | Oligodendroglioma | Favorable - better chemo response |
| WNT activation | Medulloblastoma | Excellent - >90% long-term survival |
| H3 K27M mutation | Diffuse Midline Glioma | Very poor - WHO Grade 4 by definition |
| TERT promoter mutation | GBM, Meningioma Grade 3 | Unfavorable |
| BAP1 mutation | Meningioma Grade 3 | Unfavorable |
Treatment Impact on Prognosis (Summary)
| Treatment | Applies To | Survival Benefit |
|---|---|---|
| Gross total resection | Most tumors | Significantly improves all grades |
| Temozolomide (TMZ) | GBM, anaplastic glioma | +2-3 months median survival in GBM (RCT-proven) |
| Radiotherapy (FRT) | GBM, anaplastic, medulloblastoma | Standard of care; improves survival |
| PCV chemotherapy | Oligodendroglioma (1p/19q deleted) | Robust response, especially with co-deletion |
| SRS (Gamma Knife) | Meningioma, metastases | Non-invasive option for small/inaccessible tumors |
| Methotrexate-based | CNS Lymphoma | First-line; high response rates |
Sources: Schwartz's Principles of Surgery (11th ed.), Robbins & Kumar Basic Pathology, Bradley and Daroff's Neurology in Clinical Practice, Grainger & Allison's Diagnostic Radiology. Recent review: van den Bent et al., 2024 - IDH-mutant glioma grading (Neuro-Oncology).
Note (2021 WHO Update): The latest WHO CNS5 classification integrates molecular biomarkers (IDH, 1p/19q, TERT, H3 K27M, etc.) alongside histology for grading. A morphologically "grade 2" tumor can be reclassified as grade 4 based on molecular features alone (e.g., IDH-wildtype diffuse astrocytoma with TERT mutation = GBM).
Generate a summary document on molecular biomarkers in brain tumor prognosis
Asking for Preferences
Finding Sources
Finding Sources
Searching PubMed
molecular biomarkers brain tumor prognosis IDH MGMT
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your PDF is ready:
Molecular Biomarkers Brain Tumors
PDF Document · PDF
Here's what's inside the 8-section document (formatted for medical students, with color-coded tables, diagnostic algorithms, and exam mnemonics):
Section 1 - Introduction
Why molecular biomarkers replaced pure histology; the 2021 WHO CNS5 shift.
Section 2 - Overview Table
All 9 key biomarkers at a glance (IDH, 1p/19q, MGMT, TERT, H3 K27M, CDKN2A/B, EGFR, BRAF, WNT) with impact color-coded as Favorable / Unfavorable / Targetable.
Section 3 - Detailed Biomarker Profiles
Deep dives into each marker including mechanism, clinical significance, and detection method, with comparison tables (e.g. IDH-mutant vs IDH-wildtype, MGMT methylated vs unmethylated, all 4 medulloblastoma subgroups).
Section 4 - Diagnostic Algorithm
Step-by-step WHO CNS5 molecular workup for adult diffuse glioma - exactly what happens after biopsy.
Section 5 - Therapeutic Implications
Biomarker-to-drug table: TMZ for MGMT, Vorasidenib for IDH-mutant LGG (INDIGO trial 2023), Dabrafenib+Trametinib for BRAF V600E, ONC201 for H3 K27M DMG.
Section 6 - Emerging Biomarkers
Liquid biopsy (ctDNA), DNA methylation profiling, PTEN/PI3K pathway, ATRX, and multi-omics.
Section 7 - Quick Reference
9 high-yield exam facts + the "I MADE IT" mnemonic for biomarkers that change WHO grade.
Section 8 - References
12 citations including Harrison's 22E, Bradley & Daroff, Robbins, and recent PubMed reviews (2023-2025).
Create a diagram of this page
analyse_media
Generating Image
Here's a clean diagram recreating your notes page. Here's a summary of the key content captured:
SCHWANNOMA
- Origin: Benign Schwann cell tumor with angio-centric pattern
- Site: All sites; spinal cord forms a classic dumb-bell shape (high-yield Q)
- Syndrome: NF2 - bilateral acoustic schwannoma involving Cranial Nerve 8; Chromosome 22 involved
- Microscopy: Two patterns:
- Antony A - hypercellular (lots of cells)
- Antony B - hypocellular (sparse/blank)
- Verocay bodies - 2 rows of palisading nuclei + cytoplasm, found in Antony A
MPNST
- Malignant Peripheral Nerve Sheath Tumor
Triton Tumor
- MPNST + Rhabdomyoblasts
- Associated with NF1 (not NF2)
Important Info (high-yield)
- Palisading nuclei in Brain → Schwannoma
- Palisading nuclei in Dermatology → BCC
- Pseudo-palisading → Glioblastoma
This is a shared conversation. Sign in to Orris to start your own chat.